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Objective A ginsenoside-rich extract of American ginseng (Panax quinquefolius L.), CereboostTM, was previously shown to improve
working memory and mood in healthy young individuals. The present study represented a partial replication investigating whether these
effects extended to healthy middle-aged individuals.
Methods Fifty-two healthy volunteers (40–60 years old, mean age 51.63) received 200mg of P. quinquefolius or a matching placebo
according to a double-blind, placebo-controlled, balanced, crossover design. The Cognitive Drug Research battery and the Computerised
Mental Performance Assessment System were used to evaluate cognitive performance at baseline then 1, 3 and 6 h following treatment.
Blood glucose and mood were co-monitored.
Results Compared with placebo, P.quinquefolius improved cognitive performance on ‘Working Memory’ factor at 3h. Similar effects were
observed in one of the two tasks making up this factor, spatial working memory. There were no signiﬁcant effects on mood or blood glucose levels.
Conclusions These data conﬁrm that P. quinquefolius can acutely beneﬁt working memory and extend the age range of this effect to
middle-aged individuals. These changes are unlikely to be underpinned by modulation of blood glucose in this population. Copyright ©
2015 John Wiley & Sons, Ltd.
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INTRODUCTION
Extracts of ginseng have been recognised for decades
for their effects on the central nervous system. They
have both stimulatory and inhibitory effects (Kennedy
and Scholey, 2003; Smith et al., 2014) that may modu-
late neurotransmission, enhance memory and learning
and provide neuroprotection. In a series of human
trials, we have previously conﬁrmed acute cognitive
effects of Asian (Panax) ginseng (e.g. Kennedy et al.,
2001a; 2001b; Scholey and Kennedy, 2002; Reay
et al., 2005; 2006) and, more recently American
ginseng Panax quinquefolius (Scholey et al., 2010).
The main active constituents in ginseng extracts are
believed to be the triterpenoid saponins, known as
ginsenosides (Attele et al., 1999). These can be clas-
siﬁed into three groups on the basis of their chemical
structure; the Panaxadiol group (Rb1, Rb2, Rb3, Rc,
etc.), the Panaxatriol group (Re, Rf, Rg1, Rg2,
Rh1) and the Oleanolic acid group (e.g. Ro). P.
quinquefolius typically contains 4–6% (w/w) total
ginsenosides, with ginsenosides Rb1, Re and Rd
being the most abundant (Qi et al., 2011). As with
other herbal extracts, one challenge in this area
relates to standardisation of treatment. It has been
previously shown that there can be batch-to-batch
variability in ginseng, with some extracts containing
little or no ginsenosides (Harkey et al., 2001;
Sievenpiper et al., 2004). When it comes to investi-
gations of herbal substances in the psychopharmacol-
ogy domain, it has been suggested that absence of the
standardised herbal products on the market might
have delayed the progress and consistency of the
research in this area considerably and implementation
of the standardised products provided a platform for
systematic scientiﬁc investigations (Scholey et al.,
2005). Indeed, consistency of cognitive results
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obtained with Panax ginseng to some extent is due to
the availability of its highly standardised extract
(G115); hence, the availability of a standardised P.
quinquefolius extract (Cereboost™) also provides an
opportunity to commence a systematic assessment
of its neurocognitive effects.
Cereboost™ is a dry native extract of P.quinquefolius
L. roots with a high ginsenoside content, standardised
to 10–12% total ginsenosides (Scholey et al., 2010).
This is up to threefold greater total ginsenosides than
the P.ginseng extract G115. We recently reported ﬁnd-
ings of the randomised, double-blind, placebo-
controlled, balanced, crossover trial evaluating the
acute mood, neurocognitive and blood glucose effects
of 100, 200 and 400mg of Cereboost™ in young adults
(Scholey et al., 2010). The extract was associated with
a signiﬁcant and consistent improvement to working
memory performance. Spatial working memory,
assessed using Corsi blocks, was improved by all doses
at all testing times (1, 3 and 6h post treatment). There
were also signiﬁcant improvements to numeric work-
ing memory speed and immediate word recall associ-
ated with 200mg dose. Alphabetic working memory
speed was enhanced by 100 and 400mg doses. There
were also a number of time-speciﬁc and task-speciﬁc
beneﬁts associated with other doses. Self-rated calm-
ness was increased following 100mg dose at 3 and
6h post treatment. Although potent glycaemic proper-
ties of P.quinquefolius has been previously reported
(Vuksan et al., 2000a, 2000b, 2000c), no treatment-
related changes in glucose levels were observed in the
previous study. Given that the glycaemic effects of P.
quinquefolius (Vuksan et al., 2000c) and the cognitive
impact of blood glucose changes (for example a
slightly older, middle-aged cohort, Messier et al.,
2010), may be more pronounced in individuals with
poorer glucoregulation, blood glucose was co-
monitored in the 40 to 60-year-old volunteers in the
current study.
Normal ageing is associated with neurocognitive
decline, which is likely underpinned by numerous
systemic and central structural and functional changes.
These include changes to neuronal connectivity, cellu-
lar calcium regulation, protein formation and destruc-
tion (proteolysis), neurotransmitter and hormonal
changes and cerebral blood ﬂow (Bishop et al.,
2010). Because these numerous biological changes
lead to impairments during the course of ageing, it is
likely that greater scope for cognitive enhancement
exists in older populations. For example, the effects
of other herbal extracts such as sage are greater in older
than younger individuals (Scholey et al., 2008), as are
the effects of glucose administration (e.g. Macpherson
et al., 2014). Therefore, a logical step in evaluating the
cognition-enhancing potential of pharmaceuticals, or
nutraceuticals such as P.quinquefolius is to evaluate
their effects in a slightly older cohort including, ini-
tially, with acute dosing.
The Cognitive Drug Research (CDR) battery has a
large database of normative data, which indicates that
working memory begins to decline in middle age
(Wesnes, personal communication). The battery has
been used in approximately 1400 clinical trials—many
involving the cognitive and mood effects of nutraceuti-
cal interventions, including P.ginseng (Kennedy et al.,
2001a, 2001b; 2002). The current study therefore
utilised the CDR battery in order to allow direct com-
parison with these studies. Because our previous study
found positive effects of P.quinquefolius in healthy
young adults on selected tasks form the Computerised
Mental Performance Assessment (COMPASS) battery,
these tasks were also included to gauge whether similar
effects would be observed on the same tasks in a
slightly older cohort. The use of both batteries allowed
cross-platform comparison of the two assessment
systems. The current study therefore speciﬁcally aimed
to extend previous ﬁndings by assessing the cognitive
effects of a single dose of P. quinquefolius (200mg
encapsulated CereboostTM) selected on the basis of pre-
vious ﬁndings (Scholey et al., 2010) on aspects of
working memory processes in a slightly older group
of middle-aged (40–60years) healthy volunteers.
Speciﬁcally, we hypothesised that the administration
of CereboostTM would be associated with improved
working memory performance in this population.
MATERIALS AND METHODS
Design
The investigation was a single centre, double-blind,
placebo-controlled, balanced, two-period, crossover
design study conducted at the Centre for Human Psy-
chopharmacology, Swinburne University, Australia.
The trial was registered on the Australian New Zealand
Clinical Trials Registry as ACTRN12610000849099.
Participants
A power calculation produced an N of 46 to detect a
signiﬁcant change with a power of 0.8 at the 0.005
alpha levels (adjusted from 0.05 to allow for multiple
comparisons). As a result, there was a requirement to
recruit at least 50 participants to allow for dropout.
Fifty-four volunteers (22 male and 32 female volun-
teers, mean age 51.63, SD 6.35years) took part in this
study approved by the Swinburne University Human
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Research Ethics Committee and conducted according
to the Declaration of Helsinki. All participants gave
written informed consent and received AU $200 for
their participation upon the completion of the study.
Participants completed a health screening question-
naire, and all reported that they were in good health,
not taking any drugs or medications (excluding the con-
traceptive pill), had no known food allergies and were
non-smokers. Participants with a number of medical
conditions such as diabetes, hypoglycaemia, psychiat-
ric disorders, epilepsy and gastrointestinal disorders,
who were taking prescribedmedications, were pregnant
or lactating were excluded from the study. They were
screened for cognitive decline using the Mini-Mental
State Examination (Folstein et al., 1975), and all had
scores of 27 and above, indicating that they were cogni-
tively intact. Subjects also completed the Depression
Anxiety and Stress Scale (Lovibond and Lovibond,
1995) to conﬁrm absence of the three negative affective
states of depression, anxiety and stress.
Enrolled participants refrained from taking any vita-
mins, other herbal supplements and over the counter
medicines for the period of the study. On the testing
days, participants also abstained from consuming alco-
hol, caffeine products and energy drinks.
Two participants withdrew from the study (one for
reasons unrelated to the study and one due to an
adverse event (AE) remotely related to the study prod-
uct). These volunteers were excluded from analysis,
giving a total sample size of 52 participants.
Treatments
Commercial extract of P.quinquefolius CereboostTM
provided by Naturex (Naturex, Avignon, France) was
prepared according to methods described by Scholey
et al. (2010). According to analysis of ginsenosides
by high-performance liquid chromatography per-
formed by a manufacturer, CereboostTM was
standardised to 11.65–11.67% ginsenosides with indi-
vidual ginsenoside content as follows: Rb1 (5.69%),
Re (2.06%), Rc (1.87%), Rd (1.48%), Rb2 (0.29%)
and Rg1 (0.28%). Cellulose powder (Avicel® PH
Microcrystalline Cellulose, FMC BioPolymer, PA)
served as a placebo. Encapsulation was conducted at
Thompsons Amcal Pharmacy in Melbourne, Australia.
Treatments were soft, opaque, gelatine-based capsules
of identical appearance, taste and smell. In order to
adhere to double-blind methodology standards, each in-
dividual’s treatments were prepared by a disinterested
third party who took no further part in the study. On
each of the two study days, participants received one
capsule containing either 200mg of CereboostTM or
placebo, depending on the condition to which they were
allocated on that particular day. Counterbalanced treat-
ment allocation was performed by computer-generated
randomisation.
Cognitive and mood measures
Cognitive Drug Research computerised assessment
battery. The CDR computerised assessment battery
has been used in more than 1400 drug and nutritional
interventional trials. The tailored version of the CDR
battery utilised here, including a description of the
constituent tasks, has been described in detail previ-
ously (Scholey and Kennedy, 2004; Scholey et al.,
2008). This battery has previously been found to be
sensitive to modulation of cognitive function as a con-
sequence of acute ingestion of P. ginseng (Kennedy
et al., 2001b; 2002), Ginkgo biloba (Kennedy et al.,
2000; 2001a; 2002; 2007) and a Ginkgo biloba/
P. ginseng combination (Kennedy et al., 2001a).
The selection of computer-controlled tasks was
administered in ﬁxed order with parallel versions of
the tasks randomly presented between participants at
each testing session. Presentation was via high-
resolution computer monitors and, all responses were
recorded via two-button (yes/no) response boxes with
the exception of written word recall tests. The tasks
were presented as follows: Word presentation, imme-
diate word recall, picture presentation, simple reaction
time, digit vigilance, choice reaction time, spatial
working memory, numeric working memory, delayed
word recall, word recognition and picture recognition.
In all, CDR battery tasks took approximately 20min
to complete. Detailed description of the tasks can be
found in previous publications (Kennedy et al.,
2000; 2001a; 2002; 2007; Pengelly et al., 2012;
Wesnes et al., 2000; Sunram-Lea et al., 2005).
As with previous studies assessing P.ginseng, the
single task outcomes from the CDR battery were col-
lapsed into the ﬁve cognitive outcome factors derived
by a factor analysis as previously described by Wesnes
et al. (2000) and presented graphically by Scholey and
Kennedy (2004). The factor composition is brieﬂy
outlined in the following text.
‘Working Memory’ factor: derived by combining
the sensitivity index scores from the two working
memory tests—spatial working memory and nu-
meric working memory. 100% accuracy across the
two tasks would generate a maximum score of 2
on this index.
‘Secondary Memory’ factor: derived by combining
the percentage accuracy scores from delayed word
recognition, delayed picture recognition, immediate
word recall and delayed word recall tasks. Accuracy
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of 100% across the four tasks would generate a max-
imum score of 400 on this index.
‘Speed of Memory’ factor: derived by combining
the reaction times of numeric working memory, spa-
tial memory, delayed word recognition and delayed
picture recognition (units are summed milliseconds
from the four tasks).
‘Speed of Attention’ factor: derived by combining
the reaction times of the three attentional tasks—
simple reaction time, choice reaction time and digit
vigilance (units are summed milliseconds for the
three tasks).
‘Accuracy of Attention’ factor: derived by calculat-
ing the combined percentage accuracy across the
choice reaction time and digit vigilance tasks. Accu-
racy of 100% across the two tasks would generate a
maximum score of 100.
‘Speed of Attention’ and ‘Accuracy of Attention’
factors were described as ‘Power of Attention’ and
‘Continuity of Attention‘ in the original factor analysis
by Wesnes et al. (2000); however, description utilised
in this research has been implemented in previous
research on the effects of herbal extracts on cognition
(e.g. Kennedy et al., 2002; Sunram-Lea et al., 2005;
Haskell et al., 2007).
Computerised Mental Performance Assessment System
battery. The COMPASS testing battery has been de-
veloped to include tests, which have been shown to
be sensitive to nutritional manipulations including to
acute administration of American ginseng, and tasks
are described in detail by Scholey et al. (2010). Paral-
lel versions of each of the following tasks allowed for
multiple testing. This suite of tasks took approximately
10min to complete, and they were presented as follows:
Alphabetic working memory: A series of ﬁve letters
were presented on the computer screen for 4 s for
participants to memorise. This was followed by a
series of 30 probe letters. Participants had to
indicate whether the letter was from the original
series pressing computer keyboard keys corre-
sponding to YES or NO as quickly as possible.
The task was scored for accuracy (%) and speed
(ms) of performance.
Serial 7: Participants were required to count back-
wards in sevens from a random starting number be-
tween 800 and 999, presented on the computer
screen, as quickly and accurately as possible. Partic-
ipants were using the numeric key pad to enter each
three-digit response. After the ﬁrst subtraction was
entered via the numeric key pad, each digit was re-
placed on the screen by an asterisk. The task was
scored for a number of measures: total number of
generated subtractions (n), number of correct (n) as
well as incorrect (n) subtractions, average accuracy
(%) and speed (ms) of performance, which evaluated
average time taken participant to complete one sub-
traction (ms). In case of incorrect responses, the sub-
sequent responses were scored as positive if they
were correct in relation to the new number.
RVIP: A series of digits were presented on the com-
puter screen, one at a time, at the rate of 100 digits
per min in quick succession. Participants monitored
continuous series for the target sequences: they were
required to detect consecutive sequences of three
even (combination of the following 2-4-6-8) or odd
(combination of the following 1-3-5-7-9) numbers
and asked to respond by pressing a space bar as soon
as a target string was detected. Duration of the task
was 3min with eight correct target strings presented
per minute. The task was scored for accuracy of per-
formance (% of correctly identiﬁed target strings),
the average reaction time (ms) to the correctly iden-
tiﬁed sequences, and the number (n) of false alarms.
Corsi Blocks: In all nine identical blue blocks (size
93×93 pixels) were presented dispersed randomly
on the computer screen. A predetermined number
of blocks were illuminated (brieﬂy changed colour
to red) sequentially at the rate of one per second
identifying a sequence of spatial locations to be
remembered. Volunteers repeated presented se-
quence by clicking boxes on the screen pointing cur-
sor and clicking computer mouse. Task difﬁculty
progressively increased increasing number of the
presented blocks from four upwards (maximum of
nine sequentially illuminated blocks). The task out-
come (score) was a measure of spatial span, which
reﬂected maximum of squares participants were able
to repeat correctly.
Visual analogue mood scales: The computerised
version of Bond–Lader Mood scales (Bond and
Lader, 1974) was incorporated within a number of
the selected COMPASS tasks. In all, 16 mood
scales, comprised of 100mm visual analogue scales
anchored at each end by pairs of mood antonyms
(e.g. calm-tense). These were combined as recom-
mended by the authors to form three mood factors:
‘alert’, ‘calm’ and ‘content’. Two other visual ana-
logue scales assessed stress and mental fatigue and
were described previously by Scholey et al. (2010).
Brieﬂy, participants were required to place a mark
along the line of the visual analogue scale with end
points anchored by ‘not at all’ and ‘extremely‘ in
response to the questions ‘How (stressed/mentally
fatigued) do you feel right now?’ Scores ranged
111america ginseng and working memory
Copyright © 2015 John Wiley & Sons, Ltd. Hum. Psychopharmacol Clin Exp 2015; 30: 108–122
DOI: 10.1002/hup
from 1 to 100 with higher scores reﬂecting higher
subjective feelings of stress/mental fatigue.
Pencil-and-paper questionnaires
Depression Anxiety and Stress Scales (DASS): The
shortened 21-item version of the DASS (Lovibond
and Lovibond, 1995) was used to assess three nega-
tive affective states of depression, anxiety and stress
on seven-item scales on the practice day. The De-
pression subscale (DASS-D) measures symptoms
relating to dysphoric mood (e.g. sadness), for
example ‘I couldn’t seem to experience any positive
feeling at all’. The Anxiety subscale (DASS-A) as-
sesses symptoms associated with physiological hy-
perarousal such as autonomic arousal, for example
‘I felt I was close to panic’. The Stress subscale
(DASS-S) assesses symptoms associated with ner-
vous arousal, for example ‘I tended to over-react to
situations’.
Mini-Mental State Examination is a standard tool for
screening cognitive impairments (Folstein et al.,
1975). It is a brief 30-point questionnaire test, which
facilitates the detection of mental status changes, espe-
cially in older cohorts, and frequently used to verify
absence of cognitive decline (Folstein, 2007). The
Mini-Mental State Examination was completed during
the practice day as a part of screening procedure with a
score equal or greater than 24 as an inclusion criterion.
Proﬁle of Mood States (POMS) is a self-report ques-
tionnaire designed to measure six dimensions of mood:
tension-anxiety; depression-dejection; anger-hostility;
vigour-activity; fatigue-inertia; and confusion-
bewilderment). The Proﬁle of Mood States consists
of 65 adjectives describing feeling and mood which
is answered on a ﬁve-point Likert-type scale ranging
from not at all to extremely. Respondents are asked
to indicate mood reactions for the ‘past week including
today’ or for shorter periods such as ‘right now.’ This
questionnaire was completed at the beginning of the
testing days to identify whether there were differences
in participants’ mood at the start of the day (before the
baseline assessments and subsequently treatment ad-
ministration), which could have potentially inﬂuenced
the levels of cognitive performance during the day.
State-Trait Anxiety Inventory (STAI) comprised of
two scales. The ‘State’ (STAI-S) subscale is widely
used for measuring ﬂuctuating levels of anxiety. The
subscale contains 20 statements regarding current
mood (e.g. ‘I am calm’). Participants rate how much
they feel like each statement at the time of making
the response by marking a 4-point scale ranging from
‘not at all’ to ‘very much so’. The ‘Trait’ (STAI-T)
subscale comprises 20 different statements (e.g. ‘Some
unimportant thought runs through my mind and
bothers me’). Participants were asked to indicate how
they generally feel on a scale ranging from ‘almost
never’ to ‘almost always’. Scores on both sections of
the STAI range from 20 to 80, with higher scores indi-
cating more anxiety. Participants completed this scale
at the beginning of each visit to ensure that their anxi-
ety levels did not differ prior to the commencement of
the assessments and administration of treatments.
Leeds Sleep Evaluation Questionnaire (SEQ) com-
prises of 10 self-rating 100-mm-line analogue ques-
tions concerned with aspects of sleep and early
morning behaviour. The questionnaire has been used
to monitor subjectively perceived changes in sleep dur-
ing psychopharmacological investigations. SEQ con-
tains ten questions pertaining to four aspects of sleep:
getting to sleep, quality of sleep, awakening from
sleep, and behaviour following wakefulness. This
questionnaire was completed at the beginning of each
visit prior to the cognitive and mood assessments and
administration of treatments to ensure that the quality
of the previous night’s sleep have not inﬂuenced par-
ticipants’ performance.
Blood glucose measures. As a part of the screening
procedure, fasting blood glucose measurements were
taken at the beginning of the practice day as well as
each testing day prior to breakfast intake to ensure par-
ticipants fasting blood glucose was <6.1mmol/l. This
value was chosen as the top end of a healthy fasting
range as recommended by the local Diabetes Victoria
(www.diabetesvic.org.au), also refer to Alberti and
Zimmet (1998). On each of the two active study days,
blood glucose levels were measured via capillary ﬁn-
ger prick at a baseline (before a baseline assessment),
then 1h (before the commencement of the ﬁrst post-
treatment assessment), 3h (before the commencement
of the second post-treatment assessment) and 6h
(before the commencement of the third) post-treatment
assessment following treatment administration. Blood
glucose levels were monitored using a MediSense
Optium Xceed Blood Glucose Sensor and disposable
MediSense Blood Glucose Electrodes (MediSense
Britain Ltd, Birmingham, UK). The accuracy and con-
sistency of MediSense blood glucose sensors has pre-
viously been established (e.g. (Matthews et al.,
1987). The reliability of the test has previously been
conﬁrmed (Price and Koller, 1988). Blood samples
were taken using Owen Mumford ‘Unistik 2’ single
use capillary blood sampling devices (Owen Mumford
Ltd, Oxford, UK). Alcohol-soaked skin cleansing
swabs was used for pre-sampling sterilisation.
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Blood pressure and heart rate measurement. Partici-
pants were seated calmly in a comfortable relaxed
position for at least 10min prior to the procedure.
Blood pressure was then measured with an automated
blood pressure sphygmomanometer, making sure that
an arm with a fastened blood pressure cuff was at par-
ticipants’ heart level. Systolic blood pressure was
expected to be between 91 and 139mmHg and dia-
stolic blood pressure between 61 and 89mmHg and
only participants whose blood pressure lay within nor-
mal ranges were included in the study. Heart rate was
also recorded; this measure was not used for screening
purposes.
Tolerability. Tolerability was assessed via monitoring
of unsolicited AEs (‘How have you been feeling’). To
elicit reports of adverse events and inter-current ill-
nesses, participants were required to complete the
Symptom Checklist questionnaires at the beginning
(Weekly Symptom checklist) and the end of each test
session (Daily Symptom checklist). The symptom
checklist was developed at the Brain Sciences Institute
speciﬁcally for use with natural medicines and consists
of 28 physiological/psychological problems people
might have, for example, ‘I feel dizzy’, ‘I have a dry
mouth’ and ‘I feel anxious more than usual’ (Stough
et al., 2001). Participants indicated how much the
problem had bothered them in the last 7days including
the day of recording using a 5-point scale from ‘not at
all’ to ‘very much so’.
Procedure
Each participant was required to attend the testing labs
on a total of three occasions (one practice and two
study days), conducted seven days apart to ensure
sufﬁcient wash-out between conditions. Testing took
place in a suite of dedicated laboratories at the Centre
for Human Psychopharmacology with participants
visually isolated from each other. Participants were
also wearing headphones to minimise distraction.
At the beginning of the ﬁrst visit, participants signed
their informed consent and then underwent a health
screen procedure during which their morphometric
and demographic data were collected and blood pres-
sure, heart rate and fasting blood glucose were mea-
sured. Based on the outcomes of the health screen,
participants eligible for the trial were familiarised with
the protocol and procedures of the study. Additionally,
participants ﬁlled in pen-and-paper questionnaires and
completed three cycles of the computerised tasks of
CDR and COMPASS batteries to minimise practice
effects. Performance data from the practice session
were not included in the analysis.
On arrival at their ﬁrst testing visit, participants were
randomly allocated to the treatment order determined
by a computer-generated matrix. Fasting blood glucose
was measured at the beginning of each visit to ensure
that participants fasted before attending sessions,
which was followed by standard light breakfast (piece
of toast or cereal) consumed at least 1h before the on-
set of the experiment. During this hour, prior to base-
line assessment, they completed selected pen-and-
paper questionnaires (STAI-S, POMS and Leeds
SEQ) and later underwent four identical cognitive
and mood assessments using parallel versions of the
CDR battery as well as parallel versions of selected
tasks from the COMPASS battery. Entire selection of
the computer tasks (CDR and COMPASS) took
approximately 30min to complete. The ﬁrst was a
pre-dose testing session, which established baseline
performance for the day, was immediately followed
by the day’s treatment (P.quinquefolius or placebo).
Further testing sessions began at 1, 3 and 6h following
the consumption of the treatment. A standard light
lunch was provided upon completion of 1h post-dose
assessment (between 1 and 3h cognitive and mood
assessments or approximately 1.5h post-dose), which
consisted of sandwich (with either chicken and salad,
or cheese and salad), the same foods were consumed
by each participant on each study day. Each assess-
ment was preceded by blood glucose measurements
(see Blood glucose measurements for details). The
symptom checklist was completed at the end of the
ﬁnal testing session of the day to make sure that it
was safe for participants to leave testing laboratories.
Statistical analysis
Only the data of the participants who attended all three
visits and had a suitable level of compliance with all
Table 1. Demographic and morphometric characteristics of the volunteers
(N = 52)
Measure Mean SD Min Max
Age (years) 51.63 6.47 40 60
Education (years) 16.60 3.04 11 25
Height (cm) 169.65 10.94 147 196
Body weight (kg) 71.15 14.23 45 110
Body mass index (kg/m2) 24.5 2.9 18.7 30
Systolic blood pressure (mmHg) 126.00 11.36 99 139
Diastolic blood pressure (mmHg) 78.2 8.5 63 89
Heart rate (bpm) 68.98 10.94 51 99
Fasting blood glucose (mmol/L) 5.04 0.52 4.1 6.00
MMSE (score) 29.23 0.81 27 30
DASS (score) 27.35 4.26 21 39
STAI-trait (score) 35.85 9.34 21 47
MMSE, Mini-Mental State Examination; DASS, Depression Anxiety and
Stress Scales; STAI, State-Trait Anxiety Inventory.
Mean scores are presented with standard deviations and ranges.
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study protocol requirements were selected for analy-
ses. Across the participants, screening for univariate
outliers revealed that scores for each outcome measure
were normally distributed. Data points with mean
scores more than three standard deviations outside
the sample means were excluded from the analyses;
therefore, a number of participants vary between the
tasks depending on their performance on particular
Table 2. Effects of P. quinquefolius (CereboostTM) on individual task outcome measures from the Cognitive Drug Research battery
Measure (n)
Pre-dose baseline
score
Post-dose change from baseline score
1 h 3 h 6 h
Immediate word recall
accuracy (%)
Placebo 51 41.69 (13.65) 1.96 (13.81) 4.05 (14.43) 1.57 (14.88)
P. quinquefolius 44.05 (11.78) 6.80 (11.74) 5.49 (13.04) 7.97 (13.92)
Simple reaction time (ms)
Placebo 49 266.83 (42.36) 16.17 (27.12) 11.15 (30.53) 11.05 (23.47)
P. quinquefolius 269.68 (45.01) 14.25 (25.64) 12.03 (21.76) 13.01 (27.84)
Digit vigilance
accuracy (%)
Placebo 43 98.35 (1.95) 0.93 (5.21) 1.03 (4.45) 0.26 (3.15)
P. quinquefolius 98.38 (2.23) 0.26 (2.23) 0.36 (3.29) 0.77 (3.21)
Digit vigilance FA (n)
Placebo 50 1.03 (1.05) 0.54 (1.25) 0.34(1.22) 0.40 (1.39)*
P. quinquefolius 0.76 (0.73) 0.18 (1.00) 0.00 (1.11) 0.12 (1.33)
Digit vigilance RT (ms)
Placebo 50 413.60 (40.59) 6.78 (25.16) 2.18 (31.36) 8.27 (33.76)
P. quinquefolius 413.92 (40.13) 3.63 (28.45) 9.58 (26.83) 6.61 (27.13)
Choice RT accuracy (%)
Placebo 50 98.03 (1.97) 0.44 (2.07) 0.36 (2.70) 0.40 (2.46)
P. quinquefolius 97.80 (1.84) 0.04 (2.66) 0.28 (2.52) 0.08 (2.99)
Choice RT (ms)
Placebo 49 454.80 (46.77) 12.29 (49.42) 6.02 (45.33) 16.37 (53.21)
P. quinquefolius 458.90 (68.68) 4.31 (36.22) 4.20 (41.52) 8.02 (40.38)
Spatial WM (SI)
Placebo 44 0.96 (0.05) 0.05 (0.14) 0.15 (0.35)* 0.09 (0.19)
P. quinquefolius 0.93 (0.09) 0.10(0.29) 0.01 (0.15) 0.02 (0.18)
Spatial WM RT (ms)
Placebo 49 839.65 (210.58) 39.98 (243.36) 10.65 (270.00) 94.52 (367.73)
P. quinquefolius 865.66 (216.99) 2.73 (212.47) 17.48 (206.65) 34.78 (350.89)
Numeric WM (SI)
Placebo 46 0.95 (0.04) 0.02 (0.08) 0.03 (0.08) 0.01 (0.09)
P. quinquefolius 0.95 (0.05) 0.01 (0.07) 0.00 (0.06) 0.00 (0.07)
Numeric WM RT (ms)
Placebo 49 692.85 (130.85) 7.99 (79.82) 15.45 (83.73) 17.90 (98.73)
P. quinquefolius 680.78 (115.17) 10.13 (67.51) 28.34 (61.31) 15.57 (73.60)
Delayed word recall
accuracy (%)
Placebo 50 30.06 (15.74) 8.13 (15.20) 12.00 (16.77) 10.13 (15.84)
P. quinquefolius 30.19 (12.17) 10.40 (11.12) 9.87 (12.51) 11.07 (12.53)
Word recognition (SI)
Placebo 50 0.63 (0.18) 0.00 (0.18) 0.09 (0.23) 0.05 (0.16)
P. quinquefolius 0.65 (0.17) 0.07 (0.23) 0.07 (0.22) 0.09 (0.20)
Word recognition
RT (ms)
Placebo 50 848.01 (179.71) 12.54 (152.68) 6.41 (166.92) 8.16 (169.70)
P. quinquefolius 826.36 (169.01) 14.04 (115.92) 20.78 (118.40) 53.20 (180.00)
Picture recognition (SI)
Placebo 49 0.75 (0.18) 0.04 (0.16) 0.03 (0.20) 0.07 (0.17)
P. quinquefolius 0.75 (0.21) 0.00 (0.18) 0.04 (0.17) 0.05 (0.16)
Picture recognition
RT (ms)
Placebo 49 1006.33 (215.35) 23.29 (170.33) 6.67 (162.80) 27.17 (185.22)
P. quinquefolius 989.55 (230.05) 13.69 (240.65) 0.65 (171.72) 39.96 (243.87)
Mean baseline and change from baseline scores are presented with standard deviations in parentheses. p- values between P. quinquefolius and placebo with
Bonferroni correction are indicated (*, <0.05).
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measure. This especially evident in relation to Factor
scores, which are composite scores based on perfor-
mance not one but a number of tasks; however, it
was conﬁrmed that the treatment order was not
affected by the removal of the outliers.
Scores from the pencil-and-paper questionnaires
(POMS, Leeds SEQ and STAI-S) administered prior
to the baseline assessment to ensure there were no in
participant emotional and physical state between
2days prior to treatment administration, which could
affect cognitive performance and mood, were analysed
with a one-way repeated-measures analysis of variance
(ANOVA).
Scores on all CDR individual task outcomes, the ﬁve
primary factors, the selected tasks from COMPASS
battery outcomes and blood glucose levels were
analysed as ‘change from baseline’ using the SPSS
17.0 statistical package for Windows. Prior to analysis
of ‘change from baseline’ data, raw baseline scores for
all these measures were subjected to a one-way
repeated-measures ANOVA comparing placebo with
P.quinquefolius to ensure there were no differences
of performance between the study days. Next step,
change-from-baseline scores were subjected to a two-
way repeated-measures ANOVA with factors being
‘treatment’ (CereboostTM, placebo) and ‘time’ (1, 3
and 6h) with repeated measures on both factors. For
this initial ANOVA, all testing was two-tailed at 5%
signiﬁcance level. Bonferroni corrected paired con-
trasts were made comparing P.quinquefolius with
Figure 1. Effects of P. quinquefolius (CereboostTM) on working memory
measures. Graphs depict mean scores with SEM 1, 3 and 6 h following a
single dose of P. quinquefolius and placebo. Signiﬁcant differences
(*, <0.05) at each time point are indicated
Table 3. Effects of P. quinquefolius (CereboostTM) on cognitive factors derived from the Cognitive Drug Research battery
Measure (n)
Pre-dose baseline
score
Post-dose change from baseline score
1 h 3 h 6 h
Speed of attention
(summed ms)
Placebo 48 1127.92 (100.03) 33.18 (65.38) 17.13 (54.51) 17.66 (74.49)
P. quinquefolius 1142.51 (133.95) 21.69 (60.94) 4.61 (49.54) 0.88 (49.37)
Accuracy of attention (%)
Placebo 43 92.35 (1.80) 0.23 (2.92) 0.70 (3.41) 0.51 (2.68)
P. quinquefolius 92.45 (1.34) 0.42 (1.65) 0.35 (2.64) 0.16 (1.98)
Speed of memory
(summed ms)
Placebo 48 3370.98 (541.35) 28.74 (322.65) 15.17 (366.38) 45.24 (485.60)
P. quinquefolius 3349.90 (545.73) 12.84 (353.33) 9.15 (301.62) 106.50 (613.02)
Secondary memory
(% X 4)
Placebo 48 199.59 (50.16) 20.35 (40.51) 32.81 (48.42) 26.94 (51.15)
P. quinquefolius 201.99 (50.38) 28.61 (36.92) 29.06 (42.09) 34.06 (44.07)
Working memory
(SI X 2)
Placebo 40 1.92 (0.08) 0.07 (0.19) 0.16 (0.37)* 0.10 (0.23)
P. quinquefolius 1.88 (0.11) 0.11 (0.29) 0.02 (0.12) 0.03 (0.20)
Mean baseline and change from baseline scores are presented with standard deviations in parentheses. p-values between P. quinquefolius and placebo with
Bonferroni correction are indicated (*, <0.05)
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placebo at each time point. To ensure the overall Type
I error protection level, only comparisons associated
with measures that generated a signiﬁcant main effect
of Treatment, or Treatment ×Time interaction on the
initial ANOVA are reported, along with associated
signiﬁcant and trend differences between treatments
at each time point.
RESULTS
Participant characteristics
Demographic and morphometric characteristics of the
participants are summarised in Table 1. Of the 52 par-
ticipants who completed the trial 22 (42.3%) were
male, 44 (84.6%) were right-handed and eight
(15.4%), 24 (46.2%) and 20 (38.5%) had secondary,
tertiary and postgraduate education, respectively.
Baseline scores
According to a one-way repeated-measures ANOVA
analysis of all computerised and pencil-and-paper
scores comparing placebo with P.quinquefolius, there
were no signiﬁcant differences on any measure be-
tween the two conditions prior to treatment
administration.
Cognitive Drug Research individual tasks outcome
measures
Mean pre-dose baseline raw scores and change from
baseline scores, for each treatment at each post-time
point on the individual tasks are presented in Table 2.
Where appropriate, the results of the planned compar-
ison of individual task outcomes that generated a sig-
niﬁcant result on the initial ANOVA are described in
the succeeding text in relation to the overall factor to
which they contribute.
Cognitive factors
Mean raw baseline scores and change from baseline
scores for each condition across each session are pre-
sented in the table and graphs of Table 3 and Figure 1.
Table 4. Effects of P. quinquefolius (CereboostTM) on individual task outcome measures from the Computerised Mental Performance Assessment battery
Measure (n)
Pre-dose baseline
score
Post-dose change from baseline score
1 h 3 h 6 h
Corsi Blocks score
Placebo 52 4.87 (1.95) 0.10 (1.45) 0.13 (1.55) 0.22 (1.52)
P. quinquefolius 5.15 (1.91) 0.05 (1.39) 0.24 (1.28) 0.06 (1.45)
Serial 7s accuracy (%)
Placebo 51 85.55 (13.23) 1.51 (14.77) 0.24 (14.05) 3.10 (12.65)
P. quinquefolius 84.35 (14.64) 1.37 (17.10) 3.14 (12.15) 4.95 (13.39)
Serial 7s presented (n)
Placebo 52 22.94 (12.11) 2.10 (5.21) 2.79 (4.27) 2.33 (4.70)
P. quinquefolius 23.00 (11.33) 1.10 (4.97) 3.13 (5.60) 2.63 (5.52)
Serial 7s correct (n)
Placebo 52 20.34 (12.27) 1.67 (5.96) 2.79 (5.03) 2.75 (5.59)
P. quinquefolius 19.88 (11.41) 1.25 (6.48) 3.63 (6.02) 3.27 (5.83)
Serial 7s incorrect (n)
Placebo 52 2.56 (1.90) 0.46 (2.48) 0.02 (2.19) 0.40 (2.29)
P. quinquefolius 3.09 (2.26) 0.54 (2.77) 0.50 (2.34) 0.63 (2.41)
Serial 7s speed (ms)
Placebo 52 6541.51 (3457.35) 126.71 (2517.08) 232.58 (2270.72) 587.50 (1806.76)
P. quinquefolius 6381.09 (3303.72) 136.50 (2756.68) 733.02 (2051.93) 530.36 (2953.07)
AWM accuracy (%)
Placebo 49 94.51 (4.19) 1.20 (3.62) 0.43 (4.38) 0.88 (4.06)
P. quinquefolius 94.13 (4.85) 0.57 (4.55) 1.09 (4.61) 0.84 (4.74)
AWM speed (ms)
Placebo 49 568.87 (156.17) 33.69 (96.30) 48.18 (96.12) 53.77 (83.55)
P. quinquefolius 559.55 (147.14) 8.88 (84.49) 18.22 (106.10) 29.50 (93.35)
RVIP accuracy (%)
Placebo 50 45.12 (28.53) 0.96 (31.31) 2.31 (32.63) 6.62 (28.76)
P. quinquefolius 48.07 (25.62) 2.92 (24.11) 2.48 (22.57) 2.10 (21.17)
RVIP FA (n)
Placebo 49 8.04 (7.23) 0.67 (10.26) 4.45 (18.58) 0.88 (8.03)
P. quinquefolius 10.46 (9.19) 0.45 (11.30) 0.84 (9.88) 0.18 (22.89)
RVIP speed (ms)
Placebo 48 497.68 (74.67) 15.35 (59.78) 16.74 (58.31) 9.01 (66.65)
P. quinquefolius 485.47 (60.74) 9.06 (63.44) 8.46 (56.57) 8.65 (66.88)
Mean baseline and change from baseline scores are presented with standard deviations in parentheses.
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Working memory factor: The working memory
factor was the primary outcome. The initial ANOVA
showed a signiﬁcant treatment x time interaction
[F(2,78)=3.380, p=0.039]. Compared with pla-
cebo, performance on this factor was signiﬁcantly
improved by CereboostTM at 3h (p=0.017) with
a trend towards improved performance at 6h
(p=0.08) post treatment (Table 3 and Figure 1).
Inspection of the individual task outcomes contri-
bution to the working memory factor showed that
there was a signiﬁcant Treatment×Time interaction
[F(2,86)=3.891, p=0.024] on the initial ANOVA
(Table 2 and Figure 1) for Spatial Working Memory
sensitivity index. Compared with placebo,
CereboostTM was associated with an improvement
on this task at 3 h (p=0.022) with a trend towards
a signiﬁcant improvement at 6h post treatment
(p=0.058).
Therewas no signiﬁcant Treatment or Treatment×Time
interactions for the secondary memory, speed of
memory, accuracy of attention or speed of atten-
tion factors.
COMPASS individual tasks outcome measures
Mean pre-dose baseline raw scores and change from
baseline scores, for each treatment at each post-time
point on the selected tasks of the COMPASS battery
are presented in Table 4. There were no signiﬁcant
main effects of treatment or any Treatment ×Time
interactions for any COMPASS measure.
Mood measures
None of the mood measures were signiﬁcantly affected
by treatment (Table 5).
Blood glucose levels
According to initial ANOVA [F(1,52)=0.088,
p=0.768], blood glucose levels were not affected by
the treatment and there were no treatment x time inter-
actions (Table 6).
Table 5. Effects of P. quinquefolius (CereboostTM) on the mood factors derived from the Bond–Lader mood scales (Alert, Content and Calm) and on the
‘mental fatigue’ and ‘stress’ Visual Analogue Scales mood scores
Measure (n)
Pre-dose
baseline
score
Post-dose change from baseline score
1 h 3 h 6 h
Mood factor alert
Placebo 50 66.02 (15.23) 6.75 (14.59) 9.74 (16.13) 12.83 (17.12)
P. quinquefolius 67.85 (13.38) 7.62 (14.93) 8.11 (14.15) 12.31 (17.10)
Mood factor calm
Placebo 50 65.81 (16.02) 3.06 (12.55) 3.49 (14.38) 2.71 (12.48)
P. quinquefolius 66.67 (16.75) 2.27 (9.50) 4.06 (11.56) 4.61 (13.82)
Mood factor content
Placebo 50 72.58 (13.24) 2.45 (10.96) 3.19 (11.38) 6.12 (10.43)
P. quinquefolius 73.38 (14.54) 2.86 (9.85) 3.37 (10.34) 4.08 (10.62)
VAS stress (mm)
Placebo 51 43.86 (18.95) 7.88 (16.00) 8.88 (18.35) 14.43 (23.00)
P. quinquefolius 42.42 (22.81) 6.92 (20.45) 9.65 (20.11) 12.82 (22.27)
VAS fatigue (mm)
Placebo 51 40.71 (20.34) 4.94 (19.84) 4.47 (21.07) 1.35 (19.25)
P. quinquefolius 41.63 (23.85) 0.37 (18.51) 1.65 (21.57) 1.90 (21.08)
Mean baseline and change from baseline scores are presented with standard deviations in parentheses.
Table 6. Effects of P. quinquefolius (CereboostTM) on peripheral levels of blood glucose
Measure (n)
Pre-dose
baseline
score
Post-dose change from baseline score
1 h 3 h 6 h
Blood glucose levels
(mmol/litre)
Placebo 52 6.56 (1.32) 1.73 (1.58) 0.31 (1.67) 2.04 (1.37)
P. quinquefolius 6.54 (1.19) 1.65 (1.26) 0.33 (1.28) 1.87 (1.71)
Mean baseline and change from baseline scores are presented with standard deviations in parentheses.
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Tolerability
The product was well tolerated. One AE was recorded
during the study, and was classiﬁed as remotely related
to the study product.
DISCUSSION
This randomised, crossover, placebo-controlled study in-
vestigated the acute cognitive, mood and glucoregulatory
effects of a single (200mg) dose of P.quinquefolius
(Cereboost™) in middle-aged (40–60years) volunteers.
Supporting our hypothesis, Cereboost™ improved
working memory performance as indexed by the
working memory factor score of the CDR test bat-
tery. This effect was time dependent, with signiﬁcant
improvement observed at 3 h and a trend towards im-
provement at 6 h post treatment. Whilst a working
memory factor encompassed accuracy indices (SI)
of both spatial and numeric working memory, im-
provement was largely driven contributed by the spa-
tial working memory task (Figure 1). The current
study demonstrated that a single dose of 200mg of
CereboostTM elicited modulation of cognitive perfor-
mance of healthy middle-aged adults in the absence
of mood effects.
These results partially replicate previously reported
effects of CereboostTM on cognitive functions in a
younger population, with treatment-related improve-
ments mainly observed within the cluster of the tasks
targeting working memory (Scholey et al., 2010).
The previous randomised, double-blind, placebo-
controlled, crossover trial examined the acute mood,
neurocognitive and glycaemic effects of three doses
(100, 200 and 400mg) of P. quinquefolius in healthy
young adults (mean age=25.2years, ±4.97). Like
here, there was a signiﬁcant improvement of working
memory performance associated with P. quinquefolius.
The middle 200mg dose differentially improved speed
of numeric working memory. Both the lower (100mg)
and the higher (400mg) doses enhanced alphabetic
working memory speed at all time points. In addition,
all three doses signiﬁcantly improved Corsi blocks per-
formance at all testing time points. Counter to predic-
tions, the 200mg of P.quinquefolius did not improve
performance of Corsi blocks and alphabetic working
memory in the older middle-aged cohort. However,
differences in populations (middle-aged vs. young
adults) may be partially accountable for the observed
differences. Another possible explanation could be
the structure of the testing days. In the current
study, participants attended the laboratory for appro-
ximately 8.5h, almost 2h longer than the previous
study. Extending length of the study may have induced
fatigue. The Corsi block tasks came relatively late
in a longer testing session than in the previous
study in the young cohort. It is possible that
participants expended cognitive and/or attentional
resources on other tasks leading to a null effect
on Corsi blocks.
The relatively high levels of ginsenoside Rb1 in
Cereboost™ P.quinquefolius may be partially respon-
sible for its effect on cognition. According to
Hasegawa (2004) and Tawab et al. (2003)
ginsenosides, panaxadiols, and Rb1 in particular, can
be quickly absorbed from the gastrointestinal system
and remain in the parent form after entering systemic
circulation for hours. However, these compounds
may also undergo a process of stepwise glycosylation
facilitated by intestinal ﬂora reaching systemic circula-
tion as their degradation products (compound-K (M1),
M4, Rh1 and F1), where they are esteriﬁed to fatty acid
conjugates remaining active longer than the parent
compound. Indeed, it has been demonstrated that intes-
tinal bacterial metabolic activity varies amongst indi-
viduals, and activity of orally administered
ginsenosides correlates with the ginsenoside-
hydrolyzing potential of intestinal ﬂora (Lee et al.,
2009). As the deglycosylation process is crucial for
pharmacological expression of ginsenosides, individ-
ual differences in bacterial ginsenoside-hydrolysing
potential and gastric efﬁciency determined by various
conditions including diet, health and stress levels
may lead to different levels of ginseng efﬁcacy
(Hasegawa, 2004). Hence, it is possible that gastroin-
testinal efﬁciency of the middle-aged group or this par-
ticular group of volunteers differed from that of the
participants recruited for the previous study, which de-
termined differences in effects of ginsenosides on cog-
nitive function and mood.
Choice of the single dose (200mg) for investigating
cognitive and mood effects of Cereboost™ in middle-
aged cohort might have been another reason for
discrepancies between the ﬁndings of the two studies.
Some of the cognitive measures, such as choice reac-
tion time and alphabetic working memory speed, were
improved by the lowest (100mg) and the highest
(400mg) doses in the younger cohort; therefore,
assessment of these doses might have revealed a
greater scope of beneﬁts for cognition in middle-aged
population. Therefore, implementation of the different
dosages of the extract is required to further understand-
ing of its effects in middle-aged adults.
Findings of the current study established that the
ingestion of single 200mg dose of Cereboost™ does
not modulate blood glucose in middle-aged healthy
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volunteers, with this pattern being consistent with out-
comes of the preceding study, which investigated
glucoregulatory effects of the same extract in a youn-
ger (18–40years) age group (Scholey et al., 2010).
This is despite the fact that the cohort was older than
in our previous study (Scholey et al., 2010). This sug-
gests that P.quinquefolius may not acutely modulate
blood glucose levels despite the fact that the study
was strictly controlled for glycaemic parameters. As
there were no changes in blood glucose in either study,
it seems unlikely that P.quinquefolius exerts mediating
effects on cognitive function through glucose or
insulin-mediated mechanisms.
Vuksan et al. (2000b) previously reported that P.
quinquefolius root extract attenuated postprandial
blood glucose when co-administered with 25g of glu-
cose in both healthy and diabetic volunteers; however,
hypoglycaemic effects somehow differed between two
groups. Prominent hypoglycaemic effects of P.
quinquefolius were observed in diabetic population
regardless of a dose of the herb or a time of its admin-
istration in relation to the glucose load. In contrast, a
different proﬁle of treatment-related activity emerged
in healthy volunteers: it was effective when adminis-
tered 40min prior to a glucose challenge and in fasting
conditions only. In relation to the current study, partic-
ipants were required to fast prior to the sessions in
order to control for consumption of standard breakfast
in both treatment conditions, they were provided with
food; therefore, implementation of fasting regiments
may reveal a completely different pattern of
glucoregulatory changes in response to P.
quinquefolius.
Whilst the majority of studies have focused on the
acute postprandial effects of P. quinquefolius alone or
when administered in conjunction with a glucose load,
other studies have attempted to delineate chronic ef-
fects of the herb in humans (Vuksan et al., 2001;
Vuksan and Sievenpiper, 2005). Administration of P.
quinquefolius (1g) three times daily (40min before
meals) to 24 subjects diagnosed with Type 2 Diabetes
mellitus for 8weeks resulted in signiﬁcant reduction of
fasting blood glucose and drop in levels of HbA1c ac-
companied by observable but insigniﬁcant increase of
insulin levels suggestive of improved pancreatic β-cell
function. Vuksan et al. (2001) offered an explanation
that P.quinquefolius glucoregulatory efﬁcacy may be
related to modulation of the post-absorptive early
phase of insulin secretion, the loss of which marks
Type 2 Diabetes mellitus. Noteworthy, although P.
quinquefolius generally tends to lower postprandial
blood glucose, its extract with depressed ginsenoside
proﬁle was not effective (Sievenpiper et al., 2004),
highlighting the signiﬁcance of ginsenoside expression
in P. quinquefolius extracts for glucoregulation. The
outcomes of another study into the glucoregulatory
effects of different ginseng types by Sievenpiper
et al. (2004) indicated that the ratio of
panaxadiols/panaxatriols is inversely correlated with
glucose-lowering efﬁcacy of ginsengs, which may
explain differential potency of various extracts. Inves-
tigation of the glucoregulatory effects of Cereboost™
in populations with glucoregulatory deﬁciencies and
in chronic regiments may help to specify its
glucoregulatory properties.
The underlying neurocognitive mechanisms under-
pinning the effects of P.quinquefolius on working
memory in healthy young and middle-aged adults re-
main to be established. To date, no published studies
have investigated the effects of P. quinquefolius on
brain bioactivity. However, Kennedy et al. (2003) re-
ported acute effects of standardised extract of P.gin-
seng (G115) on brain electrical activity in 15 healthy
young (mean age 26.6) volunteers. This double-blind,
placebo-controlled, balanced crossover study imple-
mented a standard auditory oddball paradigm when
participants were paying attention to the infrequent
target tones presented randomly amongst frequent
non-target tones. Administration of P.ginseng
(200mg) initiated signiﬁcant reduction of P300 la-
tency of the auditory evoked response potential across
left temporal and occipital regions without exerting
changes in its amplitude. Additionally, P.ginseng
modulated cerebral EEG activity registered in ‘eyes
closed’ condition across a number of frequency bands.
P.ginseng facilitated overall reduction in theta, beta
and alpha frequency predominantly observed at the
frontal sites. Authors suggested that these effects
may be associated with ability of ginsenosides to
modulate EEG activity through cholinergic neuro-
transmitter systems or their ability to increase cerebral
blood ﬂow hence intensify delivery of metabolic sub-
strates to cerebral structures. Whilst the study provides
evidence that P.ginseng facilitates measurable
neurocognitive changes in humans, these results are
unlikely to be pertinent to the current investigation
of P.quinquefolius, as the proﬁle of ginsenosides in
CereboostTM differs from that of P.ginseng extract
G115 with respect to individual ginsenoside content,
concentrations and the ratio of panaxadiols and
panaxatriols. For example, levels of Rb1, Rd and Re
ginsenosides in CereboostTM is comparatively higher
than that of G115 therefore pharmacological proﬁles
of the extracts are likely to differ. Differences between
the acute behavioural effects of P.quinquefolius and
P.ginseng are slowly emerging facilitated by the
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availability of the standardised extracts CereboostTM
and G115 and become evident from the broad evalua-
tion of the studies based on robust double-blind,
repeated-measures methodology with the use of the
computerised cognitive and mood assessments.
Behavioural effects of P.quinquefolius reported by
Scholey et al. (2010) and observed in the current
investigation differ from the acute effects of P.ginseng
(G115) outlined in the behavioural studies of Kennedy
et al. (2001b; 2002). Brieﬂy, P.ginseng was also capa-
ble of enhancing memory performance at levels that
are comparable with pharmaceutical cognitive en-
hancers (Neale et al., 2013). Improvements were
largely associated, however, with episodic or ‘second-
ary’ memory with changes occurring up to 6h post-
dose in response to the intake of 400mg dose
(Kennedy et al., 2001b; 2002). In contrast, the current
research suggests that cognitive effects of P.
quinquefolius are differentially associated with work-
ing memory processes.
The mechanisms behind facilitation of cognitive
performance by CereboostTM in both young and
middle-aged volunteers are unlikely to be associated
with a single physiological process. Central choliner-
gic systems have been implicated in mediating learn-
ing and memory processes (Perry, 1986) and
cholinergic effects of isolated ginsenosides have been
revealed in animal models. For example, Rb1 increased
expression of choline acetyltransferase and nerve
growth factor messenger RNA (Salim et al., 1997),
stimulated synaptosomal choline uptake and acetyl-
choline release (Benishin et al., 1991; Benishin,
1992) and modulated long-term potentiation in the rat
hippocampal formation (Abe et al., 1994). Results of
several animal studies show that Rb1 (Benishin et al.,
1991), Rg1 (Yamaguchi et al., 1995) and Re
(Yamaguchi et al., 1996) prevent scopolamine-
induced memory deﬁcits, by increasing cholinergic
activity. Future studies should elucidate the mecha-
nisms of the observed effects of CereboostTM on work-
ing memory via, for instance, scopolamine challenge
in humans.
Furthermore, we cannot rule out the possibility of
ginsenoside effects on other neurotransmitter systems
(Kennedy and Scholey, 2003). Because cognitive
improvements are most consistently found in working
memory measures, one plausible explanation could
be ginsenoside-mediated augmentation of the dopami-
nergic neurotransmitter system (Ellis and Nathan,
2001). On the other hand, considering evidence of
the cholinergic contribution to these processes (Rusted
and Warburton, 1989), and a relatively high content of
ginsenoside Rb1, possessing potent cholinergic effects
(Benishin et al., 1991) in Cereboost™ P. quinquefolius,
interaction of ginsenosides with cholinergic systems
may contribute to the observed cognitive effects.
In addition, capacity of ginsenosides to modulate ni-
tric oxide production has been previously demon-
strated (Smith et al., 2014). Considering that nitric
oxide enhances endothelial function and modulates
cerebral blood ﬂow, efﬁcient delivery of metabolic
substrates to the active cortical sites could be one of
the potential mechanisms underlying cognitive im-
provements exerted by ginseng species. Additional
measurements of cardiovascular function such as reg-
istration of cerebral blood ﬂow of the participants in
Cereboost™ and placebo conditions may provide use-
ful insight into these mechanisms.
In summary, the present results conﬁrm that
CereboostTM has the ability to positively modulate
working memory in middle-aged adults, predomi-
nantly 3h following administration. These results are
broadly consistent with previous work in younger
adults (Scholey et al., 2010) where working memory
was also improved. The mechanism of action remains
unknown, but it is unlikely that regulation of blood
glucose by P.quinquefolius is involved. Further
research is required in order to evaluate the effects of
CereboostTM at different dosages in this and other
populations.
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